---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-22-007168"
form_type: "8-K"
ticker: "ODYY"
cik: "0001626644"
company_name: "Odyssey Health, Inc."
filed_at: "2022-11-01T23:59:59+00:00"
generated_at: "2026-06-22T18:31:59.868259+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Odyssey Health files patent for intranasal brain-drug device; Phase I study successful

## Summary
- Filed US/global patent for breath-propelled intranasal brain-drug delivery device (Nasal Device).
- Phase I study of PRV-002 concussion drug via Nasal Device completed; well-tolerated in 40 healthy volunteers.
- No Nasal Device failures documented; device deposits drug deep into nasal cavity for direct CNS diffusion.
- CEO Michael Redmond cited advantage of direct brain delivery with fewer side effects for neurological treatments.

## SEC filing metadata
- accession: 0001683168-22-007168
- form_type: 8-K
- ticker: ODYY
- cik: 0001626644
- company_name: Odyssey Health, Inc.
- filed_at: 2022-11-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626644/000168316822007168/0001683168-22-007168-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626644/000168316822007168/odyssey_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-22-007168
- JSON: https://secwatch.observer/filing/0001683168-22-007168.json
- Plain text: https://secwatch.observer/filing/0001683168-22-007168.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.